Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03492840 · ClinicalTrials.gov registry record · Phase 2
Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
A Phase 2 study, sponsored by Raziel Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03492840 is a Phase 2 study that has completed, run by Raziel Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT03492840, a Phase 2 study, has completed, sponsored by Raziel Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an open label, 2 cohort, clinical trial in women with lipedema with substantial fat above the knee and men with Dercum's disease. Each cohort will have 6 subjects who will receive RZL-012.
Interventions
- DRUG RZL-012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-06-28 |
| Est. Completion | 2019-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03492840
The ClinicalTrials.gov registry entry for NCT03492840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Raziel Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RZL-012 is the first listed.
NCT03492840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03492840 about?
NCT03492840 is a clinical study titled "Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease". This is an open label, 2 cohort, clinical trial in women with lipedema with substantial fat above the knee and men with Dercum's disease. Each cohort will have 6 subjects who will receive RZL-012.
What is the current status of trial NCT03492840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-06-28. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT03492840?
The interventions under investigation include: RZL-012 (DRUG).
Who is sponsoring clinical trial NCT03492840?
This trial is sponsored by Raziel Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.